Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Food Allergenic Extract [EPC]
Peanut (Arachis hypogaea) is a non-standardized food allergenic extract used primarily in oral immunotherapy to mitigate allergic reactions, including anaphylaxis, following accidental exposure. It belongs to the class of non-standardized food allergenic extracts.
Name
Peanut
Raw Name
PEANUT
Category
Non-Standardized Food Allergenic Extract [EPC]
Drug Count
9
Variant Count
9
Last Verified
February 17, 2026
About Peanut
Peanut (Arachis hypogaea) is a non-standardized food allergenic extract used primarily in oral immunotherapy to mitigate allergic reactions, including anaphylaxis, following accidental exposure. It belongs to the class of non-standardized food allergenic extracts.
Detailed information about Peanut
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Peanut.
Peanut, clinically referred to as Arachis hypogaea allergen, is a complex biological substance used primarily in the field of allergy and immunology. In a pharmacological context, Peanut is classified as a Non-Standardized Food Allergenic Extract [EPC]. While the general public recognizes the peanut as a common dietary staple, its role in clinical pharmacology is specialized: it serves as the active pharmaceutical ingredient (API) in oral immunotherapy (OIT) protocols designed to desensitize individuals with confirmed peanut allergies. The goal of using Peanut as a drug is not to allow the patient to consume peanuts freely, but to raise the threshold of reactivity, thereby providing a 'safety net' against life-threatening systemic reactions (anaphylaxis) resulting from accidental ingestion.
Peanut belongs to a broader therapeutic category that includes Non-Standardized Plant Allergenic Extracts [EPC] and Standardized Pollen Allergenic Extracts [EPC]. According to the FDA-approved labeling for peanut-derived biologics (such as the landmark 2020 approval of Peanut Allergen Powder-dnfp), this substance is indicated for the mitigation of allergic reactions in patients aged 4 through 17 with a confirmed diagnosis of peanut allergy. The history of Peanut as a therapeutic agent shifted dramatically following the 'Learning Early About Peanut Allergy' (LEAP) study, which demonstrated that controlled exposure, rather than strict avoidance, could modify the immune system's trajectory.
At the molecular level, Peanut contains several key proteins—most notably Ara h 1, Ara h 2, and Ara h 3—which are the primary triggers for IgE-mediated allergic responses. When used as a therapeutic agent in immunotherapy, Peanut works through a process called immunological desensitization.
Initially, a patient with a peanut allergy has a high concentration of peanut-specific Immunoglobulin E (IgE) antibodies bound to the surface of mast cells and basophils. Upon exposure, these antibodies trigger the release of inflammatory mediators like histamine and leukotrienes. By introducing Peanut in minute, incrementally increasing doses, the treatment induces a shift in the immune response. Specifically, it promotes the production of Immunoglobulin G4 (IgG4), which acts as a 'blocking antibody,' and stimulates the activity of Regulatory T-cells (Tregs). These Tregs suppress the Th2-biased allergic inflammation and promote a state of desensitization. Furthermore, the prompt mentions Peanut's association with Estrogen Receptor Agonists [MoA]. This refers to the presence of phytoestrogens within the peanut matrix, such as resveratrol and various isoflavones, which can interact with estrogen receptors (ER-alpha and ER-beta), although this mechanism is secondary to its primary role in immune modulation.
Unlike traditional small-molecule drugs, the pharmacokinetics of Peanut allergenic extracts are not characterized by typical absorption and distribution curves, as the active proteins are intended to interact locally with the gut-associated lymphoid tissue (GALT) and the systemic immune system.
The primary FDA-approved indication for Peanut (as an allergenic extract) is:
Off-label uses, while less common in formal literature, may include experimental protocols for multi-food allergy desensitization where Peanut is combined with other extracts like milk or egg, though these must only be performed under strict clinical supervision in a research setting.
Peanut as a medicinal product is available in several specific forms intended for immunotherapy:
> Important: Only your healthcare provider can determine if Peanut is right for your specific condition. Immunotherapy carries a significant risk of anaphylaxis and must be initiated in a certified clinical setting.
While the primary FDA approval for Peanut immunotherapy (e.g., Palforzia) is for pediatric patients (ages 4-17), healthcare providers may continue treatment into adulthood for those who started the regimen as children.
The dosing for Peanut allergenic extract is highly structured and divided into three distinct phases:
No dosage adjustments are required for patients with renal impairment, as the allergenic proteins are metabolized proteolytically and do not rely on renal clearance for their primary mechanism of action.
No specific adjustments are documented for hepatic impairment. However, patients with severe hepatic dysfunction should be monitored for overall systemic stability, as their ability to recover from a potential anaphylactic event may be compromised.
Peanut allergenic extract is not currently indicated for initiation in patients over the age of 65. Clinical trials have not sufficiently evaluated the safety or efficacy of OIT in this demographic, particularly regarding the cardiovascular stress of potential systemic reactions.
Proper administration is critical for safety and efficacy. Patients and caregivers must follow these strict guidelines:
If a single dose is missed, it should be taken as soon as remembered on the same day, provided the 3-hour exercise window can still be observed. If more than two consecutive doses are missed, DO NOT resume the medication at home. Contact your healthcare provider immediately. Missing multiple doses can lead to a loss of desensitization, making the next dose potentially dangerous.
An overdose of Peanut allergenic extract is defined as taking a dose higher than the currently prescribed level in the up-dosing or maintenance schedule.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. The progression of doses is designed to safely 'train' your immune system.
Because Peanut immunotherapy involves the intentional exposure of an allergic individual to their allergen, side effects are extremely common, particularly during the up-dosing phase.
> Warning: Stop taking Peanut and call your doctor immediately or seek emergency care if you experience any of the following:
The primary long-term risk associated with Peanut immunotherapy is the development of Eosinophilic Esophagitis (EoE). According to clinical data from the PALISADE trials (2018-2020), some patients developed EoE that necessitated the permanent discontinuation of the therapy. Symptoms of EoE may not appear immediately but can develop over months of maintenance therapy. Additionally, there is the risk of 'chronic' low-grade gastrointestinal inflammation, which may affect a patient's quality of life and nutritional intake.
Report any unusual symptoms to your healthcare provider. Even mild symptoms can sometimes precede a more severe reaction in subsequent doses.
Peanut allergenic extract is a high-risk biologic. It is not a cure for peanut allergy, and it does not allow patients to eat peanuts freely. Patients must continue to maintain a peanut-avoidant diet. The medication is intended to provide protection against accidental exposure only. Every patient must be prescribed and carry an unexpired epinephrine autoinjector (e.g., EpiPen, Auvi-Q) at all times.
As noted in the side effects section, Peanut allergenic extracts carry a Black Box Warning regarding the risk of anaphylaxis. The FDA requires that this medication be administered under the REMS (Risk Evaluation and Mitigation Strategy) program. This ensures that only healthcare providers who are trained in managing life-threatening allergic reactions can prescribe and supervise the treatment. The warning emphasizes that systemic reactions can occur at any time during therapy, even if previous doses were well-tolerated.
Patients undergoing Peanut immunotherapy require frequent clinical monitoring:
Peanut itself does not cause sedation. However, if a patient experiences an allergic reaction or uses epinephrine, they should not drive or operate machinery. Epinephrine can cause tremors, rapid heart rate, and anxiety, which impair the ability to drive safely.
Alcohol consumption should be avoided around the time of dosing. Alcohol can increase the permeability of the gastrointestinal tract and act as a vasodilator, both of which can increase the risk of a systemic allergic reaction to the Peanut extract.
Peanut immunotherapy should not be stopped abruptly without consulting a physician. If the medication is discontinued for more than a few days, the patient will lose their desensitization. Resuming the previous dose after a break can be extremely dangerous and may cause anaphylaxis. A 're-escalation' protocol in a doctor's office is usually required to restart therapy.
> Important: Discuss all your medical conditions with your healthcare provider before starting Peanut. Ensure your asthma action plan is up to date.
Peanut immunotherapy will significantly affect allergy-related laboratory tests:
For each major interaction, the management strategy involves either selecting alternative medications (e.g., switching from a beta-blocker to a calcium channel blocker for blood pressure) or implementing rigorous monitoring during the up-dosing phase.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication review is a mandatory part of the REMS program for Peanut.
There are several conditions where Peanut allergenic extract must NEVER be used due to the extreme risk of harm:
Conditions requiring careful risk-benefit analysis include:
Patients who are allergic to other legumes (e.g., soy, peas, lentils) may experience cross-reactivity. While the treatment is specific to Peanut, the immune system's heightened state during up-dosing may make the patient more sensitive to other allergens they previously tolerated in small amounts. This is known as the 'bystander effect' in immunology.
> Important: Your healthcare provider will evaluate your complete medical history, including your history of asthma and any gastrointestinal issues, before prescribing Peanut. A physical exam and lung function test are standard prerequisites.
Peanut allergenic extract is classified as Pregnancy Category C (under the older system). There are no adequate and well-controlled studies in pregnant women.
It is not known whether peanut proteins from the extract pass into breast milk in quantities that would affect a nursing infant. However, maternal IgG4 antibodies (the 'protective' ones) do pass into breast milk, which could theoretically be beneficial. The decision to continue Peanut OIT while breastfeeding should be based on the mother's risk of accidental exposure and her ability to manage reactions while caring for an infant.
This is the primary population for Peanut allergenic extracts.
There is no clinical data on the use of Peanut allergenic extracts in patients over 65. The risks of cardiovascular strain from anaphylaxis and the likelihood of co-morbidities (and use of beta-blockers) generally make this population unsuitable for OIT.
Renal function does not significantly impact the clearance of Peanut proteins. No dose adjustments are recommended for patients with mild to moderate renal impairment. Data for end-stage renal disease (ESRD) are lacking.
As the proteins are processed by digestive enzymes and cellular proteases, the liver's CYP450 system is not involved. No specific dose adjustments are required for patients with hepatic impairment, though systemic health should be monitored.
> Important: Special populations require individualized medical assessment. Pediatric patients require constant caregiver supervision for every dose administered at home.
Peanut (Allergenic Extract) functions as an immunomodulator. The primary mechanism is the induction of immune tolerance or, more accurately, desensitization.
Additionally, as an Estrogen Receptor Agonist [MoA], the isoflavones in peanuts can bind to estrogen receptors. While this is not the primary therapeutic goal, it is a recognized biochemical property of the Arachis hypogaea matrix.
| Parameter | Value |
|---|---|
| Bioavailability | Low (subject to gastric digestion) |
| Protein Binding | N/A (Proteins interact with IgE/IgG4) |
| Half-life | Hours (proteins); Months (immune effect) |
| Tmax | 1-2 hours (for peak allergic symptom risk) |
| Metabolism | Proteolytic degradation in the GI tract |
| Excretion | Fecal (minimal), cellular turnover |
Peanut is classified as a Non-Standardized Food Allergenic Extract [EPC]. It is a biologic product. Related medications include other food allergenic extracts (milk, egg) and standardized extracts used for environmental allergies (e.g., Ragwitek, Grastek).
Common questions about Peanut
Peanut, when processed as a medicinal allergenic extract, is used for oral immunotherapy (OIT) to help desensitize individuals with a confirmed peanut allergy. The primary goal of this treatment is to reduce the risk of severe allergic reactions, such as anaphylaxis, in the event of accidental exposure to peanuts. It is important to understand that this is not a cure, and patients must still avoid eating peanuts as a regular part of their diet. The treatment is typically started in children and adolescents between the ages of 4 and 17. By taking a small, controlled amount of peanut protein every day, the immune system becomes less reactive over time.
The most common side effects associated with Peanut immunotherapy are gastrointestinal in nature, including stomach pain, nausea, and vomiting, which affect more than 80% of patients at some point during treatment. Other frequent reactions include an itchy mouth (oral pruritus), hives, and throat irritation. These symptoms are often most prominent during the 'up-dosing' phase when the amount of peanut protein is being increased. While many of these reactions are mild to moderate, they require close monitoring to ensure they do not progress to a more serious systemic reaction. Some patients may also develop a scratchy throat or a cough shortly after taking their daily dose.
No, you should avoid drinking alcohol around the time you take your daily dose of Peanut allergenic extract. Alcohol acts as a vasodilator and can increase the permeability of your stomach lining, which may cause the peanut protein to be absorbed more rapidly into your bloodstream. This significantly increases the risk of a severe, systemic allergic reaction or anaphylaxis. Furthermore, alcohol can impair your judgment and your ability to recognize the early symptoms of an allergic reaction. It is generally recommended to avoid alcohol for several hours before and after your dose to ensure maximum safety.
Peanut immunotherapy is generally not recommended for initiation during pregnancy. The primary concern is the risk of the mother having a severe allergic reaction (anaphylaxis), which can lead to a dangerous drop in blood pressure and oxygen levels, potentially causing harm or death to the fetus. If a woman is already on a stable maintenance dose and becomes pregnant, her allergist will perform a careful risk-benefit analysis to decide whether to continue the current dose. However, increasing the dose (up-dosing) is strictly avoided during pregnancy. Always inform your healthcare provider immediately if you become pregnant while undergoing this therapy.
The process of desensitization with Peanut allergenic extract is a slow and gradual one. While the immune system begins to respond to the very first doses, it typically takes about 6 to 12 months of consistent daily treatment to reach the maintenance phase where a significant level of protection is achieved. During this time, the patient goes through multiple 'up-dosing' steps in a clinical setting. Clinical trials have shown that after one year of treatment, the majority of patients can tolerate a small amount of peanut protein (roughly equivalent to two peanuts) without a systemic reaction. However, the treatment must be continued daily to maintain this protection.
You should never stop taking Peanut allergenic extract suddenly without first consulting your allergist. If you miss more than two consecutive doses, your level of desensitization can decrease rapidly, making it dangerous to resume the medication at your previous dose. Stopping the medication entirely will result in your peanut allergy returning to its original severity within a few weeks or months. If a break in treatment is necessary due to illness or surgery, your doctor will provide a specific 're-escalation' plan to safely bring you back up to your maintenance dose in a controlled medical environment.
If you miss a single dose of Peanut, you can take it later that same day as long as you can still follow the safety rules, such as taking it with a meal and avoiding exercise for three hours afterward. However, if you do not remember until the next day, do not double the dose to make up for the missed one. Simply take your regular dose for that day. If you miss two or more doses in a row, you must stop and call your healthcare provider before taking any more medication. Resuming therapy after multiple missed doses increases the risk of anaphylaxis and must often be done in a doctor's office.
There is no clinical evidence to suggest that Peanut allergenic extract causes weight gain as a direct pharmacological side effect. The amount of peanut protein used in the treatment (300 mg) is nutritionally negligible, containing only a few calories. However, some patients might experience changes in their diet or appetite if they suffer from chronic gastrointestinal side effects like nausea or abdominal pain. If you notice significant weight changes or persistent stomach issues, you should discuss these with your doctor, as they could be signs of Eosinophilic Esophagitis (EoE), a condition that requires medical management.
Peanut can interact with several other medications, some of which are very serious. You must avoid beta-blockers and certain antidepressants (like MAOIs) because they can prevent life-saving epinephrine from working correctly if you have an allergic reaction. Other medications, like daily antihistamines, might mask the early signs of an allergy, making it harder to tell if your dose is causing a problem. Always provide your allergist with a full list of all prescription drugs, over-the-counter medicines, and herbal supplements you are taking. They will help you determine which medications are safe to use alongside your immunotherapy.
Currently, Peanut (as a specific FDA-approved allergenic extract for OIT) is not available in a traditional generic form. While 'peanut flour' exists as a food product, it is not a substitute for the pharmaceutical-grade, standardized allergenic extract used in medical treatments. The approved products are biologics, and any 'biosimilar' or generic versions would have to undergo rigorous clinical testing to prove they are safe and effective for desensitization. Because the treatment is managed under a strict REMS safety program, you should only use the specific product prescribed by your healthcare provider and obtained through a certified pharmacy.